This page shows the latest Viltolarsen news and features for those working in and with pharma, biotech and healthcare.
In August, the US Food and Drug Administration (FDA) approved Japanese pharmaceutical company Nippon Shinyaku’s (NS Pharma) DMD drug Viltepso (viltolarsen).
Drug approved for patients with exon 53 mutation. Japanese pharma Nippon Shinyaku (NS Pharma) has scored US Food and Drug Administration (FDA) approval for its Duchenne muscular dystrophy drug viltolarsen, now
Viltolarsen has been granted a priority review, as well as fast track, orphan drug and rare disease designations. ... Viltolarsen is an antisense oligonucleotide that promotes the production of functional dystrophin by masking exon 53 in the dystrophin
It’s exon 53 skipping drug viltolarsen was filed for approval in October and could be approved in the middle of next year.
It could face its first competition fairly soon however after rival NS Pharma filed for approval of its exon 53 skipping drug viltolarsen in October.
In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been filed with the FDA for the treatment of DMD. ... Although the FDA has not yet set an approval decision date, if there are no significant issues
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....